Multiplex Assay Kit for Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay)

ARMETL1; ARMET-like protein 1; Conserved Dopamine Neurotrophic Factor; Arginine-Rich,Mutated In Early Stage Tumors-Like 1

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-88 85
EDTA plasma(n=5) 80-96 86
heparin plasma(n=5) 85-92 88

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 93-101% 88-99% 88-96% 80-93%
EDTA plasma(n=5) 81-99% 89-97% 86-101% 91-102%
heparin plasma(n=5) 89-97% 88-102% 80-90% 78-88%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:CDNF) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Journal of Neuroinflammation Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra Pubmed: 25511018
JOURNAL OF NEUROINFLAMMATION Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra Pubmed:25511018
TURKISH JOURNAL OF MEDICAL SCIENCES THE EFFECT OF KISSPEPTIN ON SPERMATOGENESIS AND APOPTOSIS IN RATS fileID:693211
Neural Regen Res Cerebral dopamine neurotrophic factor transfection in dopamine neurons using neurotensin-polyplex nanoparticles reverses 6-hydroxydopamine-induced … 34472486
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPG458Hu01 Recombinant Cerebral Dopamine Neurotrophic Factor (CDNF) Positive Control; Immunogen; SDS-PAGE; WB.
EPG458Hu61 Eukaryotic Cerebral Dopamine Neurotrophic Factor (CDNF) Positive Control; Immunogen; SDS-PAGE; WB.
APG458Hu61 Active Cerebral Dopamine Neurotrophic Factor (CDNF) Cell culture; Activity Assays.
PAG458Hu01 Polyclonal Antibody to Cerebral Dopamine Neurotrophic Factor (CDNF) WB; IHC; ICC; IP.
PAG458Hu06 Polyclonal Antibody to Cerebral Dopamine Neurotrophic Factor (CDNF) WB; IHC; ICC; IP.
MAG458Hu22 Monoclonal Antibody to Cerebral Dopamine Neurotrophic Factor (CDNF) WB; IHC; ICC; IP.
MAG458Hu26 Monoclonal Antibody to Cerebral Dopamine Neurotrophic Factor (CDNF) WB; IHC; ICC; IP.
MAG458Hu21 Monoclonal Antibody to Cerebral Dopamine Neurotrophic Factor (CDNF) WB; IHC
SEG458Hu ELISA Kit for Cerebral Dopamine Neurotrophic Factor (CDNF) Enzyme-linked immunosorbent assay for Antigen Detection.
MEG458Hu Mini Samples ELISA Kit for Cerebral Dopamine Neurotrophic Factor (CDNF) Enzyme-linked immunosorbent assay for Antigen Detection.
LMG458Hu Multiplex Assay Kit for Cerebral Dopamine Neurotrophic Factor (CDNF) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.